Gentian Diagnostics ASA (FRA:6FK)

Market Cap	71.53M
Revenue (ttm)	14.72M
Net Income (ttm)	3.65M
Shares Out	n/a
EPS (ttm)	0.23
PE Ratio	19.59
Forward PE	52.63
Dividend	0.03 (0.76%)
Ex-Dividend Date	May 7, 2025

Volume	n/a
Average Volume	n/a
Open	4.510
Previous Close	4.410
Day's Range	4.510 - 4.510
52-Week Range	3.200 - 5.420
Beta	n/a
RSI	46.30
Earnings Date	Feb 11, 2026

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chro...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2001
• Employees: 63
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6FK

Financial Performance

Financial numbers in NOK